Sarepta Therapeutics (SRPT) Net Income towards Common Stockholders Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Sarepta Therapeutics | 1.86 Bn | 1.17 Bn | 291.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.59% |
| Dec 31, 2025 | -8.36% |
| Sep 30, 2025 | 1.74% |
| Jun 30, 2025 | 27.23% |
| Mar 31, 2025 | -91.25% |
| Dec 31, 2024 | 22.35% |
| Sep 30, 2024 | 17.81% |
| Jun 30, 2024 | 15.15% |
| Mar 31, 2024 | 19.89% |
| Dec 31, 2023 | 18.37% |
| Sep 30, 2023 | 11.73% |
| Jun 30, 2023 | 26.19% |
| Mar 31, 2023 | -70.98% |
| Dec 31, 2022 | 73.50% |
| Sep 30, 2022 | -40.11% |
| Jun 30, 2022 | -29.71% |
| Mar 31, 2022 | -26.58% |
| Dec 31, 2021 | 3.41% |
| Sep 30, 2021 | 3.23% |
| Jun 30, 2021 | -5.49% |
| Mar 31, 2021 | -22.85% |
| Dec 31, 2020 | -24.05% |
| Sep 30, 2020 | -30.58% |
| Jun 30, 2020 | -29.07% |
| Mar 31, 2020 | 22.32% |
| Dec 31, 2019 | -39.43% |
| Sep 30, 2019 | -30.27% |
| Jun 30, 2019 | -55.63% |
| Mar 31, 2019 | -24.99% |
| Dec 31, 2018 | -33.81% |
| Sep 30, 2018 | -25.16% |
| Jun 30, 2018 | -44.90% |
| Mar 31, 2018 | -18.43% |
| Dec 31, 2017 | -18.47% |
| Sep 30, 2017 | -47.50% |
| Jun 30, 2017 | -63.17% |
| Mar 31, 2017 | 70.49% |
| Dec 31, 2016 | -58.46% |
| Sep 30, 2016 | -38.66% |
| Jun 30, 2016 | -44.25% |
| Mar 31, 2016 | -61.50% |
| Dec 31, 2015 | -108.11% |
| Sep 30, 2015 | -69.36% |
| Jun 30, 2015 | -40.77% |